Immunotherapy and Immune Checkpoint Inhibitors

Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized cancer treatment by enhancing the body’s immune response against tumors. These inhibitors target proteins like PD-1, PD-L1, and CTLA-4 that cancer cells use to suppress immune activity. By blocking these checkpoints, T-cells are reactivated to identify and attack cancer cells more effectively. This approach has shown significant success in treating cancers such as melanoma, lung, and renal cancers. However, not all patients respond equally, and some experience immune-related side effects. Ongoing research focuses on improving patient selection, combining therapies, and developing new checkpoint targets to broaden the impact of immunotherapy.

    Related Conference of Immunotherapy and Immune Checkpoint Inhibitors

    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 20-21, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    December 08-09, 2025

    13th Euro Breast Cancer and Therapeutics

    Aix-en-Provence, France
    February 19-20, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    February 19-20, 2026

    8th International Conference on Women Oncology

    Miami, USA
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France

    Immunotherapy and Immune Checkpoint Inhibitors Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in